Filing Flows

Filing Flows › Comparisons › MMM vs SYK

3M vs Stryker: MMM and SYK compared

3M is the larger company: $6.6B of revenue in its latest quarter (Q3 2026) against $6.5B for Stryker (Q3 2026). Stryker is growing faster (+8% against +1% a year earlier). 3M is more profitable, with an operating margin of 23.7% against 15.9%.

3M vs Stryker, latest quarter3M vs Stryker, latest quarter3M (MMM)Stryker (SYK)Revenue$6.6B$6.5BRevenue growth, Y/Y+1%+8%Operating margin23.7%15.9%Net margin20.9%11.5%Free cash flow$230M$1.2B

Where the money goes: MMM and SYK

3M (MMM) · Q3 2026

3M, Q3 2026: revenue $6.6B (+1% year over year), operating margin 23.7%, net earnings $1.4B, operating cash flow $486M. The chart follows the revenue to costs, profit and cash.

Stryker (SYK) · Q3 2026

Stryker, Q3 2026: revenue $6.5B (+8% year over year), operating margin 15.9%, net earnings $753M, operating cash flow $1.5B. The chart follows the revenue to costs, profit and cash.

Stryker revenue by segment, Q3 2026Stryker revenue by segment, Q3 2026MedSurg and Neurotechnology:$3.7BOrthopaedics:$2.9B
3M (MMM)Stryker (SYK)
Latest quarterQ3 2026Q3 2026
Revenue$6.6B$6.5B
Revenue growth, Y/Y+1%+8%
Gross margin—65.2%
Operating margin23.7%15.9%
Net earnings$1.4B$753M
Net margin20.9%11.5%
Operating cash flow$486M$1.5B
Free cash flow$230M$1.2B
Market value$98.1B$128.9B
P/E28.0×35.7×
Analysts’ mean target$194.51$340.48

Where the revenue comes from

Stryker

Questions

Which is bigger, 3M or Stryker?

3M is the larger company: $6.6B of revenue in its latest quarter (Q3 2026) against $6.5B for Stryker (Q3 2026).

Is 3M or Stryker growing faster?

Stryker is growing faster (+8% against +1% a year earlier).

Which is more profitable, 3M or Stryker?

3M is more profitable, with an operating margin of 23.7% against 15.9%.

More: 3M earnings · how 3M makes money · Stryker earnings · how Stryker makes money

From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 20, 2026; 10-Q filed Oct 30, 2026). Fiscal quarters can end on different dates. Not investment advice.